Case Report: Acral MYH10::ALK fusion superficial mesenchymal neoplasm: first proof of metastatic potential - Scorecard - MDSpire

Case Report: Acral MYH10::ALK fusion superficial mesenchymal neoplasm: first proof of metastatic potential

  • By

  • Masih Kameh Khosh

  • Sascha Wellenbrock

  • Daniel Kameh Khosh

  • Tobias Hirsch

  • Abbas Agaimy

  • Dan Mon O'Dey

  • June 2, 2026

  • 0 min

Share

Clinical Scorecard: Case Study: First Evidence of Metastatic Capability in Acral MYH10::ALK Fusion Superficial Mesenchymal Tumor

At a Glance

CategoryDetail
ConditionSuperficial ALK-rearranged soft tissue tumors
Key MechanismsMYH10::ALK fusion gene
Target PopulationYoung adults
Care SettingSurgical and oncological follow-up

Key Highlights

  • Rare mesenchymal neoplasms with heterogeneous morphology
  • Typically present as slowly enlarging nodules
  • Diagnosis requires integrated histologic, immunophenotypic, and molecular assessment

Guideline-Based Recommendations

Diagnosis

  • Integrated histologic, immunophenotypic, and molecular assessment required

Management

  • Surgical resection is the primary treatment approach

Monitoring & Follow-up

  • Long-term surveillance is necessary due to potential for recurrence

Risks

    Patient & Prescribing Data

    Healthy young adults with superficial ALK-rearranged tumors

    Surgical resection may be complicated by residual tumor

    Clinical Best Practices

      Related Resources & Content

      Original Source(s)

      Case Report: Acral MYH10::ALK fusion superficial mesenchymal neoplasm: first proof of metastatic potential

      • by Masih Kameh Khosh, Sascha Wellenbrock, Daniel Kameh Khosh, Tobias Hirsch, Abbas Agaimy, Dan Mon O'Dey

      • June 2, 2026

      Related Content

      Chemotherapy-related cognitive impairment and non-pharmacological interventions targeting the nervous system: a systematic review

      Target receptor expression dictates the selective intra-tumoral targeting of CD8+ T cells by eciskafusp alfa in matched PBMCs and TILs from CPI-naïve patients

      RAS(ON) Inhibitor Doubles Median Overall Survival in Results of Phase 3 Trial for Patients with Metastatic Pancreatic Cancer

      At the ASCO annual meeting, Dana-Farber’s Brian Wolpin, MD, MPH, presented positive results from the RASolute 302 trial showing a substantial prolongation of survival for patients with previously treated metastatic pancreatic cancer, regardless of RAS mutation status, taking daraxonrasib, an investigational oral RAS(ON) multi-selective inhibitor, compared with chemotherapy.

      • by

      • June 1, 2026

      • 5 min